Email Alert RSS
Volume 13 Issue 4
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2022  >  13(4): 679-686
LUO Xiangchong, WANG Zhouqing, LI Qiongyan, MAO Guibing, AN Le, ZHU Jiahong, TAO E'hong, SUN Lifei, WANG Shengfei, LI Gaofeng. Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 679-686. doi: 10.12290/xhyxzz.2021-0691
Citation: LUO Xiangchong, WANG Zhouqing, LI Qiongyan, MAO Guibing, AN Le, ZHU Jiahong, TAO E'hong, SUN Lifei, WANG Shengfei, LI Gaofeng. Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 679-686. doi: 10.12290/xhyxzz.2021-0691
shu

Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors

doi: 10.12290/xhyxzz.2021-0691
  • 1.

    Department of Cardiothoracic Surgery, Qujing Second People's Hospital, Qujing, Yunnan 655000, China

  • 2.

    Department of Second Thoracic Surgery, Yunnan Cancer Hospital, Kunming 650118, China

Funds:

National Natural Science Foundation of China 81760554

The"Famous Doctor"Special Project of Ten Thousand People Plan of Yunnan Province C20096

Medical Leading Talents Training Program of Yunnan Provincial Health Commission L-2019028

More Information
  • Corresponding author: LI Gaofeng, E-mail: ligaofenghl@126.com
  • Received Date: 2021-10-13
  • Accepted Date: 2021-11-23
    • Available Online: 2022-06-27
  • Publish Date: 2022-07-30
    Abstract
  • In recent years, immunotherapy has made breakthroughs in the field of malignant tumors, and more and more novel immune checkpoint inhibitors have been developed, revolutionizing the first-line, second-line and post-line treatment options for malignant tumors. Tislelizumab is a domestically developed inhibitor of programmed death-1 (PD-1). The drug has shown good antitumor potential and safety in classical Hodgkin's lymphoma, uroepithelial carcinoma, non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma and gastric cancer/gastroesophageal junction carcinoma. In this review, the structure and mechanism of action, pharmacodynamics and pharmacokinetics, clinical research and adverse reactions of tislelizumab are reviewed to provide reference for clinical application.
    • FullText(HTML)
  • loading
    • References(44)
  • [1] Siegel KL, Miller KD, Jemal A, et al. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70: 7-30. doi:  10.3322/caac.21590
    [2] Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy[J]. Int J Clin Oncol, 2020, 25: 790-800. doi:  10.1007/s10147-019-01588-7
    [3] Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer[J]. Int J Clin Oncol, 2020, 25: 818-830.
    [4] Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy[J]. Int J Clin Oncol, 2020, 25: 790-800. doi:  10.1007/s10147-019-01588-7
    [5] Keam SJ. Toripalimab: first global approval[J]. Drugs, 2019, 79: 573-578. doi:  10.1007/s40265-019-01076-2
    [6] Hoy SM. Sintilimab: first global approval[J]. Drugs, 2019, 79: 341-346.
    [7] Markham A, Keam SJ. Camrelizumab: first global approval[J]. Drugs, 2019, 79: 1355-1361. doi:  10.1007/s40265-019-01167-0
    [8] Lee A, Keam SJ. Tislelizumab: first approval[J]. Drugs, 2020, 80: 617-624.
    [9] Pinto JA, Raez LE, Oliveres H, et al. Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer[J]. Expert Opin Biol Ther, 2019, 19: 509-515. doi:  10.1080/14712598.2019.1610380
    [10] Jayesh D, Benjamin M, Michael F, et al. Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an inves-tigational anti-PD-1 antibody, in a first-in-human Phase Ⅰ study[J]. Cancer Res, 2019, 79: CT084.
    [11] Lee SH, Lee HT, Lim H, et al. Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy[J]. Biochem Biophys Res Commun, 2020, 527: 226-231.
    [12] Zhang T, Song X, Xu L, et al. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions[J]. Cancer Immunol Immunother, 2018, 67: 1079-1090.
    [13] Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non- comparative, phase 1/2 study[published correction appears in J Immunother Cancer[J]. J Immunother Cancer, 2020, 8: e000437.
    [14] Lee SH, Lee HT, Lim H, et al. Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy[J]. Biochem Biophys Res Commun, 2020, 527: 226-231.
    [15] Wu CY, Budha N, Gao Y, et al. Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors[J]. Ann Oncol, 2019: v182-v183.
    [16] Lee HT, Lee SH, Heo YS. Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology[J]. Molecules, 2019, 24: 1190-1195.
    [17] Feng YC, Hong Y, Sun HZ, et al. The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is diferentiated from pembrolizumab and nivolumab[J]. Cancer Res, 2019, 79: 2383.
    [18] Zhang T, Song J, Li YC, et al. Anti-human PD-1 antibody BGB-A317 exhibits potent immune cell activation[J]. Cancer Res, 2016, 76: 2226.
    [19] Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, bms-936558, and in vivo toxicology in non-human primates[J]. Cancer Immunol Res, 2014, 2: 846-885.
    [20] Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma[J]. Expert Opin Drug Metab Toxicol, 2016, 12: 1247-1253.
    [21] Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2020, 95: 978-989.
    [22] Chen J, Zhang H, Zhu L, et al. Tislelizumab for the treatment of classical Hodgkin's lymphoma[J]. Drugs Today (Barc), 2020, 56: 781-785.
    [23] Takahara T, Murase Y, Tsuzuki T. Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes[J]. Pathology, 2021, 53: 56-66.
    [24] Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial[J]. Lancet, 2017, 389: 67-76.
    [25] Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2017, 18: 1483-1492.
    [26] Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2017, 18: 312-322.
    [27] Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study[J]. JAMA Oncol, 2017, 3: e172411.
    [28] Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial[J]. Lancet Oncol, 2018, 19: 51-64.
    [29] Ye D, Liu J, Zhou A, et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma[J]. Cancer Sci, 2021, 112: 305-313.
    [30] Koleczko S, Wolf J. Immune checkpoint inhibitors in lung cancer[J]. Internist (Berl), 2020, 61: 676-681.
    [31] Liu SY, Wu YL. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)[J]. Expert Opin Investig Drugs, 2020, 29: 1355-1364.
    [32] Wang Z, Zhao J, Ma Z, et al. A Phase 2 study of Tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients[J]. Lung Cancer, 2020, 147: 259-268.
    [33] Wang J, Lu S, Yu XM, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2021, 7: 709-717.
    [34] Lu S, Wang J, Yu Y, et al. Tislelizumab Plus Chemo-therapy as First-Line Treatment for Locally Advanced or Metas-tatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial[J]. J Thorac Oncol, 2021, 16: 1512-1522.
    [35] Ko KL, Mak LY, Cheung KS, et al. Hepatocellular carcinoma: recent advances and emerging medical therapies[J]. F1000Res, 2020, 9: F1000 Faculty Rev-620.
    [36] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389: 2492-2502.
    [37] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224): a non-rando-mised, open-label phase 2triaI[J]. Lancet Oncol, 2018, 19: 940-952.
    [38] Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study[J]. J Immunother Cancer, 2020, 8: e000437.
    [39] Qin S, Finn RS, Kudo M, et al. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma[J]. Future Oncol, 2019, 15: 1811-1822.
    [40] Sun J, Zheng Y, Mamun M, et al. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors[J]. Biomed Pharmacother, 2020, 129: 110504.
    [41] Xu J, Bai Y, Xu N, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma[J]. Clin Cancer Res, 2020, 26: 4542-4550.
    [42] Wang SY, Huang XM, Bai YX, et al. Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC)[J]. J Clin Oncol, 2019, 37: 2556-2556.
    [43] Oh Do-Youn, Chung HC, Im YH, et al. ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress[J]. J Clin Oncol, 2020, 38: TPS3145.
    [44] Baek JH. Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer[J]. J Yeungnam Med Sci, 2022, 9: 62-66.
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (691) PDF downloads(80) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return